ArteraAI Presents New Data Validating AI-Derived Predictive Biomarker ...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: October 4, 2023

Riddle & Brantley Partners with Groundbreaking Nonprofit to Combat the Growing Mental Health Crisis Facing Today's Youth • Cartamundi and Warner Bros. Discovery Global Consumer Products Unveil the DC “Selfie Moments” Limited-Edition Hybrid • Illume Fertility Founder and Medical Director, Dr. Mark Leondires, Co-Authors the First All-Inclusive Guide to Donor Conception • Qwoted Launches Free Networking Tools for PR Industry • MERGE Acquires Zee Jay Digital to Orchestrate the Content Supply Chain for Superior CX • Grupo EULEN announces Angeles Campoy as the New Chief Executive Officer for USA • Avangrid Schedules Third Quarter 2023 Earnings Release and Conference Call • Global Clean Energy Reports Largest Camelina Acreage Worldwide • CAMS Wins Ragan CSR, ESG and Diversity Awards • UCB presents late-breaking posters at Child Neurology Society Meeting • Six wheelchair tennis players nominated to Santiago 2023 Canadian Parapan Am Team • Statement - Ministers Anandasangaree, Vandal, Hajdu, and Ien issue a statement of support on Sisters in Spirit Day and the Natio • Dr. Toba N. Niazi Appointed Chief of the Section of Neurosurgery and Co-Director of Nicklaus Children's Brain Institute • HTeaO Kicks Off 'Round Up with the Ryan Palmer Foundation' • Get a Free Google Pixel 8 and Unleash its Full 5G Potential Only at T-Mobile, America’s 5G Leader • BioTek reMEDys Calls for Heightened Communication Around Health Literacy Month • Vancouver International Airport Selects LAT Multilingual to Engage with Chinese Travellers • THE COMMUNITY SPIRIT VODKA JOINS FORCES WITH ONE GRAND BOOKS TO CELEBRATE LGBTQ+ HISTORY MONTH THROUGH LITERATURE • Patrick and Brittany Mahomes’ 15 and the Mahomies Foundation Establishes National Partnership With Boys & Girls Clubs • ACE Cash Express Supports Homes For Our Troops to Help Veterans Rebuild Their Lives

ArteraAI Presents New Data Validating AI-Derived Predictive Biomarker at 2023 ASCO Annual Meeting

SAN FRANCISCO , June 01 /Businesswire/ - ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announces new data validating a multimodal AI-derived predictive biomarker, which has been selected as an oral presentation at the 2023 ASCO annual meeting. The biomarker demonstrated the ability to predict the benefit of long-term androgen deprivation therapy (ADT) in men with localized high-risk prostate cancer.

In patients with high-risk localized prostate cancer, ADT is considered a cornerstone of treatment, along with radiotherapy. When making treatment decisions, clinicians and patients must consider the duration of therapy, which is known to have a wide range of negative side effects. To help guide a treatment plan that will maximize benefits and minimize risks, predictive biomarkers are needed. The authors of the research, including Dr. Andrew Armstrong, MD, Professor of Medicine and Surgery at Duke University, sought to develop an AI-based predictive biomarker to address this unmet need.

“This is the first-ever AI-derived biomarker that can predict clinical benefit from longer-duration therapy,” said Dr. Andrew Armstrong, MD, Professor of Medicine and Surgery at Duke University and lead author of this research. “We are eager for the further development of this biomarker as it could lead to a tool that has the potential to change how clinicians make treatment decisions. Furthermore, it could help save patients from the physical, emotional, and financial burden of a long-term treatment that would not have therapeutic benefit.”

Clinical data and histopathology image data from pretreatment prostate biopsy slides were used to train the model to predict the benefit of long-term vs short-term ADT treatment on distant metastasis. Developed using patient data from six randomized, phase 3 NRG/RTOG trials of men receiving RT +/- ADT, the AI-derived predictive biomarker identified 34% of men that could derive similar benefit with short-term ADT, avoiding the side effects of prolonged ADT. Additionally, the model identified 43% of intermediate-risk men who would benefit from long-term ADT.

For more information on ArteraAI, visit Artera.ai.

About ArteraAI

ArteraAI is a leading precision medicine company developing AI tests to personalize cancer therapy. ArteraAI offers an AI-enabled test that is the first of its kind to provide both predictive and prognostic results for patients with localized prostate cancer: ArteraAI Prostate Test.

ArteraAI’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and learns from a patient's clinical data. The AI combines this information to predict whether a patient will benefit from a particular therapy and determine their prognosis and has been validated in many phase 3 randomized trials.

ArteraAI Prostate Test is the first test that can both predict therapy benefit and prognosticate long-term outcomes in localized prostate cancer. The test is clinically available through our CLIA-certified laboratory in Jacksonville, Florida and can be ordered online at Artera.ai.